INCRELEX is not indicated for use in patients with secondary forms of IGFD, such as GH deficiency, malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids
Since a treatment could receive a GOR of D for several reasons, we specified if the treatment received this rating because the evidence was a single case report or series (SC), demonstrated a neutral effect (NE), or was found to be possibly detrimental (DE)
The peak areas from each of these transitions were obtained, and ratios of the analytes to the internal standard were calculated for every sample
This product provides glutathione in its reduced active form, which
Sig Transduct Target Ther 8 , 345 (2023)
A: Safety data in humans is limited